For a better experience, Read this story in our App
+ 1,046.30
+ 319.15
-30.00
-229.00
-1,143.00
+ 1,046.30
+ 319.15
+ 319.15
-30.00
-30.00
-229.00
Gland Pharma announced its approval from the US drug agency for a new injection | Photo Credit: Ildo Frazao
Gland Pharma, a generic injectable-focused pharmaceutical company, has received approval from the United States Food and Drug Administration (USFDA) for Eribulin Mesylate Injection.
The product is expected to be the first generic approval on the market, and the Hyderabad-based company expects to launch this product in the near term through its marketing partner. It had US sales of approximately $92 million for 12 months ending in February 2024, according to IQVIA.
Gland Pharma is co-developing several complex injectables, including this product, with Orbicular Pharmaceutical Technologies Private Ltd, according to a release.
Eribulin Mesylate Injection is generally indicated for the treatment of some types of cancer under specific conditions.
Published on April 8, 2024
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.